Management of drug eruptions: Part II. Diagnosis and treatment.
In this second of two articles on adverse cutaneous drug reactions, the management of drug eruptions is reviewed. This necessitates, above all, a full history and may involve observation of the effects of drug elimination. Skin testing may be helpful in some circumstances, but is hampered by false positive and negative results, and lack of knowledge of the significant antigenic determinants for most drugs. In vitro tests are for the most part unreliable and are research tools. Challenge tests are safe in fixed drug eruption, but are absolutely contraindicated in Stevens-Johnson syndrome and toxic epidermal necrolysis. The approach to the treatment of the more serious adverse cutaneous drug reactions, including angioedema/anaphylaxis, exfoliative dermatitis erythroderma and toxic epidermal necrolysis is reviewed. For those patients who develop reactions to an essential medication for which there is no alternative, desensitization is possible.
Breathnach
S M
SM
St John's Institute of Dermatology, United Medical School of Guy's, St Thomas' Hospital, London, UK.
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D003888:Desensitization, Immunologic; D003875:Drug Eruptions / Q000175:diagnosis* / Q000628:therapy*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis; D011239:Prednisolone / Q000008:administration & dosage; D011852:Radioallergosorbent Test; D012882:Skin Tests
D000893:Anti-Inflammatory Agents; D007073:Immunoglobulin E; D011239:Prednisolone